Emergent BioSolutions (EBS) Tops Q4 EPS by 23c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.38 -0.95%
Revenue Growth %: +32.0%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: +32.0%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $4.50, $0.23 better than the analyst estimate of $4.27. Revenue for the quarter came in at $723.2 million versus the consensus estimate of $691.36 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Constellation Brands (STZ) Tops Q1 EPS by 18c
- Flowserve acquires Trillium valves division for $490 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
